ES2894963T3 - Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn - Google Patents

Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn Download PDF

Info

Publication number
ES2894963T3
ES2894963T3 ES18201967T ES18201967T ES2894963T3 ES 2894963 T3 ES2894963 T3 ES 2894963T3 ES 18201967 T ES18201967 T ES 18201967T ES 18201967 T ES18201967 T ES 18201967T ES 2894963 T3 ES2894963 T3 ES 2894963T3
Authority
ES
Spain
Prior art keywords
seq
subject
variants
tnfsf15
crohn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18201967T
Other languages
English (en)
Spanish (es)
Other versions
ES2894963T8 (es
Inventor
Dermot P Mcgovern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Application granted granted Critical
Publication of ES2894963T3 publication Critical patent/ES2894963T3/es
Publication of ES2894963T8 publication Critical patent/ES2894963T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18201967T 2013-05-17 2014-05-16 Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn Active ES2894963T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17

Publications (2)

Publication Number Publication Date
ES2894963T3 true ES2894963T3 (es) 2022-02-16
ES2894963T8 ES2894963T8 (es) 2022-02-24

Family

ID=51899024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18201967T Active ES2894963T3 (es) 2013-05-17 2014-05-16 Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn

Country Status (7)

Country Link
US (4) US20160090629A1 (enExample)
EP (3) EP2997165A4 (enExample)
JP (5) JP6482533B2 (enExample)
KR (4) KR20210107176A (enExample)
CN (1) CN105358713B (enExample)
ES (1) ES2894963T3 (enExample)
WO (1) WO2014186750A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
KR20230003433A (ko) * 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CN121371183A (zh) * 2018-09-07 2026-01-23 费城儿童医院 用于淋巴系统病症的诊断和治疗的组合物和方法
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
CN122060049A (zh) * 2019-09-13 2026-05-19 协和麒麟株式会社 DcR3变体
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
HRP20150684T1 (hr) * 2008-02-19 2015-09-11 The Children's Hospital Of Philadelphia, Abramson Pediatric Research Center, Office of Technology Transfer Identifikacija specifiäśnih mjesta nastanka - genetski loci - upalne bolesti crijeva kod djece i postupci njihove uporabe u takvoj dijagnozi te njihovo lijeäśenje
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
WO2012054532A1 (en) 2010-10-18 2012-04-26 Prometheus Laboratories Inc. Methods for determining anti-drug antibody isotypes
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
AU2012259312A1 (en) * 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法

Also Published As

Publication number Publication date
US12281359B2 (en) 2025-04-22
KR20250130857A (ko) 2025-09-02
WO2014186750A3 (en) 2015-01-08
US20160090629A1 (en) 2016-03-31
EP3498867A1 (en) 2019-06-19
EP2997165A4 (en) 2017-03-08
CN105358713B (zh) 2020-02-28
CN105358713A (zh) 2016-02-24
JP2025023316A (ja) 2025-02-14
EP3498867B1 (en) 2021-09-29
EP3988673A3 (en) 2022-08-03
US20180230543A1 (en) 2018-08-16
KR20230093538A (ko) 2023-06-27
JP2022111329A (ja) 2022-07-29
EP2997165A2 (en) 2016-03-23
WO2014186750A2 (en) 2014-11-20
KR20160009582A (ko) 2016-01-26
JP2020127437A (ja) 2020-08-27
US20210371931A1 (en) 2021-12-02
JP2018148931A (ja) 2018-09-27
JP6482533B2 (ja) 2019-03-13
ES2894963T8 (es) 2022-02-24
US20250243548A1 (en) 2025-07-31
KR20210107176A (ko) 2021-08-31
EP3988673A2 (en) 2022-04-27
JP2016526875A (ja) 2016-09-08
KR102295125B1 (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
JP2022111329A (ja) クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
Werbrouck et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
Karayasheva et al. Association study for the role of matrix metalloproteinases 2 and 3 gene polymorphisms in dental caries susceptibility
Baatjes et al. CYP19A1 rs10046 pharmacogenetics in postmenopausal breast cancer patients treated with aromatase inhibitors: one-year follow-up
Lim et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population
Szczepańska et al. Involvement of vascular endothelial growth factor-460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis
Teixeira et al. SH3BP2-encoding exons involved in cherubism are not associated with central giant cell granuloma
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
CN102787163B (zh) 检测OTOF基因c.1671_1673delG突变的试剂盒
Kacerovska et al. Carney complex: a clinicopathologic and molecular biological study of a sporadic case, including extracutaneous and cutaneous lesions and a novel mutation of the PRKAR1A gene
CN106244727A (zh) 一种hpv‑16与宿主遗传因素的联合效应的测试方法
Guan et al. Risk of gastric ulcer contributed by genetic polymorphisms of PSCA: A case-control study based on Chinese Han population
Francis et al. Hypoxia responsiveness linked variant in EGLN1 gene is enriched in oral cancer patients
CN102732613A (zh) 检测OTOF基因c.5833delG突变的试剂盒
Bagheri et al. Association study of transforming growth factor alpha TaqI polymorphism and the risk of cleft lip and/or palate in an Iranian population
Omelchenko et al. POLYMORPHISMS IN THE GENES OF VASCULAR ENDOTHELIAL GROWTH FACTOR ARE ASSOCIATED WITH THE EARLIER ONSET OF RHEUMATOID ARTHRITIS
CN102732615A (zh) 检测OTOF基因c.2382_2383delC突变的试剂盒
Omran et al. Relationship between STK39 Genotype and Vitamin D3 in Hypertension
Lucky et al. (VDR) Gene Polymorphisms–Rapid and noninvasive oral detection Method
Izquierdo et al. 813 MOLECULAR CHARACTERIZATION OF UPPER URINARY TRACT TUMOURS
Rouprêt et al. 812 GENETIC VARIABILITY WITHIN 8Q24 CONFERS ENHANCED RISK OF UROTHELIAL CELL CARCINOMA OF THE UPPER URINARY TRACT
Cornu et al. 814 IMPORTANCE OF ALLELIC INSTABILITY OF URINARY MICROSATELLITES MARKERS FOR CONSERVATIVE MANAGEMENT OF UPPER URINARY TRACT UROTHELIAL CELL CARCINOMA